Structured Answers

1. Definition & Etiology

Acute Post-Streptococcal Glomerulonephritis (APSGN) is the most common form of acute GN in children — an immune complex-mediated disease following infection with nephritogenic strains of Group A β-hemolytic Streptococcus.

• •Agent: Nephritogenic strains of Group A β-hemolytic Streptococcus
• •Trigger: Pharyngitis (5-21 days, average 10 days) or skin infection/impetigo (3-6 weeks)
• •Age: Peak 2-12 years; more common in boys; rare <2 years
• •Pathophysiology: Streptococcal antigens → immune complex deposition (IgG + C3) in subepithelial locations forming "humps" on EM → complement activation → neutrophil influx → decreased GFR

2. Clinical Features

• •Classic Triad (Nephritic Syndrome): Hematuria (smoky/tea-colored, RBC casts pathognomonic), Edema (periorbital, pitting, sudden), Hypertension (salt-water retention)
• •Associated: Oliguria, mild proteinuria (<1 g/day), azotemia (fatigue, nausea, anorexia), fever, flank pain, hypertensive encephalopathy (headache, seizures, papilledema), CCF/heart failure (severe HTN + fluid overload)

2A. AGN vs Nephrotic Syndrome — Key Differentiator

The examiner repeatedly tests the ability to distinguish AGN from NS. This comparison table is high-yield.

3. Investigations

4. Management

• •General: Bed rest, salt and fluid restriction (to insensible + urine output). Daily monitoring: BP, weight, strict I/O chart.
• •Hypertension: First-line: Nifedipine (calcium channel blocker) oral. Emergency: IV Labetalol or Nitroprusside.
• •Hyperkalemia: Calcium gluconate → insulin + glucose → sodium bicarbonate. Dialysis if refractory.
• •Fluid overload: Furosemide 1-2 mg/kg IV.
• •Azotemia/AKI: Dialysis if refractory fluid overload, severe hyperkalemia, or uremic symptoms.
• •Strep eradication: Benzathine Penicillin G 600,000 U IM (<27 kg) or 1.2 million U IM (>27 kg) single dose. Alternative: Penicillin V 25-50 mg/kg/day PO divided BD-TDS (max 500 mg/dose) x 10 days. If allergic: Erythromycin or Azithromycin.
• •Negative points: NO corticosteroids/immunosuppressants in APSGN. ACE inhibitors are NOT first-line for acute HTN (can worsen hyperkalemia + AKI). Diuretics are NOT first-line for HTN (used only for fluid overload).

5. Complications & Prognosis

• •AKI — reversible; dialysis rarely needed
• •Hypertensive encephalopathy — seizures, papilledema
• •CCF / Heart failure — due to severe HTN + fluid overload
• •Acute pulmonary edema — fluid overload
• •CKD — rare (<1%); consider if crescents on biopsy
• •Prognosis: Excellent; >95% complete recovery. Gross hematuria resolves in 5-10 days. Microscopic hematuria may persist months-years. C3 normalizes by 6-8 weeks. If C3 remains low >8-12 weeks, suspect MPGN.

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Confusing AGN with NS — remember: AGN has hematuria + HTN + low C3; NS has massive proteinuria + hypoalbuminemia + no HTN
• •Trap 2: Using ACE inhibitors as first-line for AGN HTN — NO; first-line is Nifedipine (CCB). ACEi can worsen hyperkalemia and AKI.
• •Trap 3: Using diuretics for HTN — NO; diuretics are only for fluid overload, not HTN control.
• •Trap 4: Prescribing steroids for PSGN — NO; therapy is supportive only.
• •Trap 5: Forgetting pediatric penicillin dosing — weight-based: 600K U (<27 kg) or 1.2M U (>27 kg) IM.
• •Trap 6: Normal C3 + normal C4 + hematuria → think IgA nephropathy (not PSGN).
• •High-yield: PSGN can develop even after antibiotic treatment of strep infection.

1. Definition & Classification

Nephrotic Syndrome (NS) is defined by nephrotic-range proteinuria (>50 mg/kg/day or urine protein/creatinine ratio >2.0 mg/mg), hypoalbuminemia (<2.5 g/dL), hyperlipidemia, and edema.

2. Clinical Features

• •Edema - periorbital (worse in morning), dependent (legs by evening), ascites, pleural effusion, scrotal edema
• •Frothy urine - due to massive proteinuria
• •Weight gain - fluid retention
• •Anorexia, lethargy, diarrhea - gut edema
• •Hypovolemia signs - cold peripheries, tachycardia, hypotension (despite edema!)
• •Infections - loss of IgG and complement factors in urine
• •Thrombosis - loss of antithrombin III; renal vein thrombosis most common

3. Investigations

4. Management

• •General: Bed rest during edema phase. Normal protein intake (do NOT restrict). Salt restriction during edema. Daily weight, BP, urine protein dipstick, I/O chart.
• •Edema: Loop diuretics (Furosemide) for severe edema; monitor for hypovolemia.
• •Steroid Regimen (First Episode — ISKD Protocol): Prednisolone 2 mg/kg/day (max 60 mg/day) x 6 weeks → 1.5 mg/kg alternate days x 6 weeks → taper. Total 12 weeks for responders (best long-term results).
• •Hypovolemia/Shock: 25% albumin 0.5-1.0 g/kg IV over 1-2 hours + IV loop diuretic.
• •Infection (SBP/cellulitis): Ceftriaxone. Vaccinate with Pneumococcal + Varicella. Organisms: S. pneumoniae, E. coli, Klebsiella.
• •Thrombosis: LMWH, then warfarin.
• •Adjunctive: ACE inhibitors (Enalapril) for persistent HTN/proteinuria. Spironolactone (K+-sparing diuretic) may be used cautiously.
• •Steroid-Sparing Agents: Cyclophosphamide 2 mg/kg/day PO x 8-12 weeks (cumulative 168 mg/kg). Cyclosporine 3-5 mg/kg/day. Tacrolimus 0.1 mg/kg/day. MMF 600-1200 mg/m²/day. Rituximab for severe cases.

5. Complications & Prognosis

• •Infections: Spontaneous bacterial peritonitis (S. pneumoniae, E. coli, Klebsiella), cellulitis, sepsis. Loss of IgG, Factor B, properdin.
• •Thromboembolism: Renal vein thrombosis (most common). Loss of antithrombin III, proteins C & S.
• •Hypovolemia/AKI: Acute pre-renal failure. Hypotension, cold peripheries.
• •Other: Growth retardation (chronic steroids), cataracts, osteoporosis, hypothyroidism (loss of TBG), hypocalcemia/tetany (loss of vitamin D-binding protein).
• •Prognosis: MCD: Excellent; 80% achieve remission with steroids; relapses decrease with age. FSGS: ~35% respond to steroids; 50% progress to ESRD within 10 years.

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Confusing NS with AGN — NS has NO hematuria, NO HTN, normal C3; AGN has all three.
• •Trap 2: Wrong steroid dose — must specify 2 mg/kg/day (MAX 60 mg/day); not 1 mg/kg.
• •Trap 3: Wrong steroid duration — total 12 weeks for responders, not 6 weeks only.
• •Trap 4: Using ACE inhibitors for acute HTN in NS — use CCBs (Amlodipine) first; ACEi is for persistent HTN/proteinuria.
• •Trap 5: Forgetting salt restriction — as important as steroids for edema control.
• •Trap 6: Protein restriction — NO; maintain normal protein intake.
• •High-yield: S. pneumoniae is the #1 organism for SBP in NS — vaccinate!
• •High-yield: Biopsy BEFORE steroids if low C3, >8 years, or atypical features.

1. Definition

Rickets is defined as decreased or defective bone mineralization in growing children; osteomalacia is the adult equivalent.

2. Biochemical Changes

Low dietary Vit D / Sunlight → Low 25-OH Vit D (<8 ng/mL suggests deficiency) → Low intestinal Ca absorption → Hypocalcemia → High PTH secretion (secondary hyperparathyroidism) → Renal phosphate wasting + Bone resorption → Hypophosphatemia → Low Ca x PO4 product (<30 mg²/dL²) → Defective mineralization of osteoid → Rickets

3. Clinical Features

• •Head & Chest: Craniotabes (ping-pong ball sensation, 3-6 months), delayed fontanelle closure (>18 months), rachitic rosary (costochondral beading, ribs 5-8), Harrison's sulcus, pectus carinatum/excavatum
• •Extremities & Spine: Wrist widening, ankle widening, bow legs (genu varum, <3 years), knock knees (genu valgum, >3 years), delayed teething (>12 months), kyphosis/scoliosis, bone pain/tenderness
• •Systemic: Delayed motor milestones (sitting, walking), proximal muscle weakness/myopathy, failure to thrive
• •Emergency: Hypocalcemic seizures/tetany (severe rickets) — treat with IV calcium gluconate 1-2 mL/kg of 10% solution slowly over 10 minutes with cardiac monitoring

3A. Diagnosis & Management Algorithm

4. Radiological Findings (X-ray Wrist - AP View)

• •Cupping - concavity of metaphysis (saucerization)
• •Fraying - irregular, brush-like appearance of metaphyseal margins
• •Splaying - widening of growth plate (>2 mm)
• •Reduced bone density - coarsened trabecular pattern
• •Greenstick fractures

5. Management

• •Emergency (hypocalcemic seizures/tetany): IV calcium gluconate 1-2 mL/kg of 10% solution given slowly over 10 minutes with ECG monitoring for bradycardia.
• •Monitoring: Clinical improvement in 2-4 weeks; radiological healing in 3-6 months. Monitor serum Ca, PO4, ALP at 4, 8, 12 weeks.
• •Surgical: Corrective osteotomy for severe deformities (after healing of rickets).
• •Prevention: Breastfed infants: 400 IU/day Vit D3 from first few days. Formula-fed: supplement if <1 L/day. Pregnant/lactating mothers: 600-1000 IU/day. Sun exposure: 15-30 min/day. High-risk: dark skin, limited sun, malabsorption.

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Confusing rickets with scurvy — scurvy has white line of Fraenkel on X-ray and bleeding gums; rickets has cupping/fraying/splaying.
• •Trap 2: Normal calcium in early rickets — PTH rises FIRST to maintain calcium; do not expect hypocalcemia initially.
• •Trap 3: Vit D dependent Type I — normal 25(OH)D but low 1,25(OH)2D; differs from nutritional deficiency.
• •Trap 4: XLH — normal calcium, normal 25(OH)D, low phosphate only; treat with phosphate + calcitriol (NOT calcium).
• •Trap 5: Forgetting elemental calcium supplementation alongside vitamin D.
• •High-yield: Rachitic rosary is most prominent at ribs 5-8.
• •High-yield: 25(OH)D <20 ng/mL indicates deficiency; <10 ng/mL indicates severe deficiency (some references use <8 ng/mL for severe).
• •High-yield: Radiological healing takes 3-6 months — slower than clinical improvement.

1. Definition & Etiology

Congenital Hypothyroidism (CH) is thyroid hormone deficiency present at birth. Most common preventable cause of intellectual disability. Incidence: 1:2500-1:4000 live births.

2. Clinical Features

CRITICAL: The examiner tests neonatal features, NOT childhood features. Do NOT mention short stature or intellectual disability — those develop if untreated.

• •Neonatal Period (First 2-4 Weeks) — THESE ARE THE EXAM ANSWERS: Prolonged physiological jaundice (>7 days) — unconjugated, hypotonia, lethargy, poor feeding, constipation, hypothermia (cold, mottled skin), large anterior + posterior fontanelle, bradycardia, respiratory distress (myxedema of vocal cords), edema (periorbital, peripheral), hoarse cry, macroglossia, umbilical hernia
• •Infantile Period (2-3 Months Onwards): Coarse facies (flat nasal bridge, puffy eyes, macroglossia), umbilical hernia, goiter (in dyshormonogenesis), developmental delay, hoarse cry, dry skin, sparse hair, short stature, anemia (macrocytic)

3. Newborn Screening

• •All newborns screened at day 3-5 of life (before discharge, optimally 48-72h after birth to avoid physiological TSH surge)
• •Primary screening: TSH (most common) or T4
• •Abnormal: TSH >20-40 mIU/L; T4 <10 microg/dL
• •Confirmatory: Serum TSH, free T4, total T4
• •If TSH high + T4 low: Primary hypothyroidism
• •If TSH low/normal + T4 low: Central hypothyroidism - do MRI pituitary

3A. Neonatal vs Childhood Features — Examiner Trap

4. Management

• •Levothyroxine (L-thyroxine): 10-15 microg/kg/day PO started immediately after confirmation
• •Start treatment within 2 weeks of life for normal neurodevelopmental outcome
• •Crush tablet, mix with breast milk/formula. Do NOT give with soy/iron/calcium (reduces absorption)
• •Monitoring: TSH and free T4 every 1-2 months in first 6 months; then every 3 months until age 3; then every 6-12 months
• •Target: TSH 0.5-2.0 mIU/L; free T4 in upper normal range
• •Prognosis: Excellent if treatment starts within 2 weeks; IQ normal

4A. Screening & Management Algorithm

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Listing childhood features (short stature, intellectual disability) instead of neonatal features — examiner wants neonatal features specifically.
• •Trap 2: Forgetting unconjugated hyperbilirubinemia — not conjugated.
• •Trap 3: Wrong screening timing — day 3-5, not immediately at birth (physiological TSH surge).
• •Trap 4: Missing central hypothyroidism — low/normal TSH + low T4 = MRI pituitary.
• •Trap 5: Giving levothyroxine with soy/iron/calcium — reduces absorption.
• •High-yield: Most common preventable cause of intellectual disability — start before 2 weeks.
• •High-yield: TSH screening cutoff: >20-25 mIU/L (recall threshold >40 mIU/L indicates severe deficiency).

1. Differential Diagnosis of Acute Scrotum

2. Clinical Features of Testicular Torsion

• •Sudden severe unilateral scrotal pain (often wakes child from sleep)
• •Nausea and vomiting (due to severe pain)
• •High-riding testis (horizontal lie - "bell-clapper deformity")
• •Absent cremasteric reflex (most sensitive sign)
• •Scrotal swelling, erythema, tenderness
• •No relief with elevation (vs epididymitis where elevation helps - Prehn's sign)

3. Investigations

• •Color Doppler USG - test of choice; shows absent or decreased blood flow to testis (sensitivity 90-100%)
• •Radionuclide scan - rarely used now; "cold spot" in torsion
• •Urine analysis - normal (vs pyuria in infection)
• •Do NOT delay surgery for imaging if clinical suspicion is high

4. Emergency Management

• •Immediate surgical exploration - do not wait for imaging if strongly suspected
• •Manual detorsion may be attempted as a temporizing measure ("open the book" - rotate testis laterally 180 degrees x 2)
• •Scrotal exploration: Detorsion, assess viability (warm packs). Orchidectomy if non-viable/necrotic. Bilateral orchidopexy (fix both testes to prevent future torsion).
• •Salvage rate: >90% if surgery within 6 hours; <10% if >24 hours (applies to peripubertal intravaginal torsion; neonatal torsion rarely salvageable).

4A. Emergency Management Algorithm

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Confusing torsion with epididymo-orchitis — torsion has sudden onset + absent cremasteric + normal urine; epididymitis has gradual onset + fever + pyuria.
• •Trap 2: Forgetting bilateral orchidopexy — always fix both testes to prevent future torsion on the contralateral side.
• •Trap 3: Delaying surgery for imaging — do NOT wait for Doppler if clinical suspicion is high.
• •Trap 4: Age trap — torsion occurs in neonates AND adolescents (two peaks), not just teenagers.
• •Trap 5: Blue dot sign = torsion of appendix testis, NOT testicular torsion — different management (conservative).
• •High-yield: Absent cremasteric reflex is the most sensitive clinical sign.
• •High-yield: <6 hours = >90% salvage; >24 hours = <10% salvage.

1. Classification of Hematuria

• •Glomerular Hematuria: Color: Cola/tea/smoky (brown). RBCs: Dysmorphic, fragmented (acanthocytes). Casts: RBC casts pathognomonic. Proteinuria: Present (often >+++). Clots: Absent. Associated: Edema, hypertension, decreased GFR.
• •Non-Glomerular Hematuria: Color: Fresh red/pink. RBCs: Isomorphic (normal shape). Casts: Absent. Proteinuria: Minimal or absent. Clots: May be present. Associated: Dysuria, flank pain, trauma history.

2. Differential Diagnosis

• •Glomerular causes: AGN/PSGN, IgA Nephropathy (Synpharyngitic hematuria), HSP/IgA vasculitis, Alport Syndrome (X-linked, hearing loss), MPGN, Thin Basement Membrane Disease
• •Non-glomerular causes: UTI, Urolithiasis, Trauma, Hypercalciuria (#1 cause of isolated hematuria), Coagulopathy, Sickle Cell Trait/Disease, Wilms Tumor, PUV/UPJ obstruction

3. Key Investigations

3A. Diagnostic Approach Algorithm

🎯 Examiner Traps & High-Yield Points

• •Trap 1: RBC casts = pathognomonic for glomerular hematuria. If you see RBC casts, it is glomerular until proven otherwise.
• •Trap 2: Clots in urine = non-glomerular. Glomerular hematuria does NOT form clots.
• •Trap 3: IgA nephropathy = normal C3. Low C3 points to PSGN or MPGN.
• •Trap 4: Hypercalciuria is the #1 cause of isolated non-glomerular hematuria in children.
• •Trap 5: Alport syndrome = X-linked, hearing loss, family history of hematuria + deafness.
• •High-yield: Brown/smoky urine = glomerular; fresh red/pink = non-glomerular.
• •High-yield: Dysmorphic RBCs = glomerular; isomorphic RBCs = non-glomerular.

1. Definition

• •Operational threshold: Plasma glucose <40 mg/dL in the first 24 hours; <45 mg/dL after 24 hours
• •Neuroglycopenic threshold: <30 mg/dL - risk of permanent brain injury

2. Risk Factors

• •Increased Utilization / Decreased Stores: Preterm/SGA/IUGR (decreased glycogen stores), perinatal asphyxia, hypothermia, sepsis, polycythemia
• •Hyperinsulinism / Endocrine: Infant of Diabetic Mother (IDM), LGA, Beckwith-Wiedemann syndrome, transfusion/exchange, pituitary/adrenal insufficiency, inborn errors of metabolism

3. Clinical Features

Asymptomatic hypoglycemia is common - detected only on screening

4. Management

• •Screening: All at-risk neonates at 2, 6, 12, 24, 36, 48 hours
• •Asymptomatic (glucose 25-40): Feed immediately; recheck in 30 min
• •Symptomatic or <25 mg/dL: IV D10 2 mL/kg bolus then D10 maintenance 80-100 mL/kg/day
• •Goal: Maintain glucose >45-50 mg/dL
• •If persistent: Increase GIR to 8-12 mg/kg/min; add glucagon 0.03 mg/kg IV or hydrocortisone 5 mg/kg/day
• •Refractory: Evaluate for hyperinsulinism then Diazoxide / Octreotide / Surgery

5. Neonatal Hypoglycemia Management Algorithm

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Definition confusion — old: <40 mg/dL (first 24h); new AAP: <47 mg/dL (operational threshold); treatment threshold: <54 mg/dL.
• •Trap 2: Asymptomatic hypoglycemia is common — do NOT overtreat; feed and recheck.
• •Trap 3: SGA causes hypoglycemia via glycogen depletion; IDM causes it via hyperinsulinism — different mechanisms.
• •Trap 4: Giving dextrose bolus to asymptomatic baby — feed first; IV dextrose only if symptomatic or <25 mg/dL.
• •Trap 5: Forgetting Beckwith-Wiedemann syndrome as a cause of refractory hypoglycemia (hyperinsulinism + macrosomia + macroglossia + omphalocele).
• •High-yield: Hypoglycemia + macrosomia + macroglossia = Beckwith-Wiedemann.
• •High-yield: Refractory hypoglycemia → think hyperinsulinism → Diazoxide first-line.

1. Definition

Intussusception is the telescoping (invagination) of a proximal segment of bowel (intussusceptum) into the distal segment (intussuscipiens). It is the most common cause of intestinal obstruction in children aged 6-36 months.

• •Idiopathic (90%): Lymphoid hyperplasia of Peyer patches (post-viral)
• •Lead point (10%): Meckel diverticulum, polyp, lymphoma, duplication cyst, HSP

2. Clinical Features

• •Classic Triad: Severe episodic crying (colicky pain), vomiting (bilious if advanced), currant jelly stool (blood + mucus)
• •Other: Drawing up of legs toward abdomen during episodes, lethargy between episodes, sausage-shaped abdominal mass (right upper quadrant), empty right lower quadrant (Dance sign)

3. Investigations

• •USG Abdomen - test of choice; shows "target sign" or "doughnut sign" (concentric rings)
• •Abdominal X-ray - signs of obstruction (air-fluid levels), paucity of gas in RLQ, soft tissue mass
• •Contrast Enema - diagnostic and therapeutic; shows "coiled spring sign" or "meniscus sign"
• •Air Enema - preferred for reduction under fluoroscopy
• •Do NOT perform contrast enema if signs of perforation or peritonitis

4. Management

• •Non-operative (First Line): Air/contrast enema reduction under fluoroscopy. Success rate: 80-90%. Contraindications: Peritonitis, perforation, shock, failed enema reduction.
• •Operative: Manual reduction via laparotomy or laparoscopy. Resection if gangrenous bowel or lead point.
• •Pre-operative: IV fluids, NG tube decompression, antibiotics, correct electrolytes.

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Forgetting the two peaks — idiopathic intussusception is most common at 6-36 months; older children with intussusception likely have a lead point (Meckel, lymphoma, HSP).
• •Trap 2: Contrast enema is contraindicated if there are signs of peritonitis or perforation — surgery first in these cases.
• •Trap 3: Missing Dance sign (empty RLQ) — a subtle but important clinical sign.
• •Trap 4: Confusing with gastroenteritis — gastroenteritis has continuous diarrhea and no mass; intussusception has episodic colic, vomiting, and a sausage-shaped mass.
• •Trap 5: Delaying reduction — time is bowel; risk of gangrene increases after 24 hours.
• •High-yield: Currant jelly stool = late sign (sloughed mucosa + blood); do not wait for it.
• •High-yield: Ileocolic is the most common type (90%).

1. Definition & Pathophysiology

Portal Hypertension is a pathological increase in portal venous pressure (>10 mmHg or gradient >5 mmHg). It results from increased resistance to portal blood flow and/or increased portal blood flow.

• •Pre-hepatic: Portal vein thrombosis, congenital atresia/stenosis, compression by tumor/cyst
• •Hepatic (most common): Cirrhosis, congenital hepatic fibrosis, schistosomiasis
• •Post-hepatic: Budd-Chiari syndrome, constrictive pericarditis, veno-occlusive disease

2. Clinical Features

• •Splenomegaly - most common sign; hypersplenism (pancytopenia)
• •Ascites - fluid accumulation in peritoneal cavity
• •Caput medusae - dilated periumbilical veins
• •Hematemesis/Melena - from esophageal/gastric variceal bleeding (life-threatening)
• •Hepatic encephalopathy - confusion, asterixis, altered consciousness
• •Pruritus, jaundice, palmar erythema, spider angiomas - signs of chronic liver disease

3. Investigations

4. Management

• •Acute Variceal Bleeding: IV fluids, blood transfusion (Hb target 7-8 g/dL), antibiotics (Ceftriaxone - prevent SBP), vasoactive drugs (Octreotide/Terlipressin), endoscopic band ligation (EBL) or sclerotherapy. Balloon tamponade (Sengstaken-Blakemore) if refractory — rarely used in young children due to technical difficulty and risk of esophageal injury; consider only in ICU with anesthesia support. TIPS if endoscopy fails.
• •Prevention of Rebleeding: Non-selective beta-blockers (Propranolol 1-2 mg/kg/day divided BID-TID, max 160 mg/day), repeated EBL until varices obliterated.
• •Primary Prophylaxis: Non-selective beta-blockers (Propranolol 1-2 mg/kg/day) or EBL if high-risk varices.
• •Portosystemic Shunt Surgery: Devascularization procedures (Sugiura), shunt procedures (MESO-Rex bypass for portal vein thrombosis), liver transplantation (definitive for end-stage liver disease).
• •General: Low sodium diet, diuretics (Spironolactone + Furosemide) for ascites, lactulose/rifaximin for encephalopathy, nutritional support.

5. Complications

• •Variceal bleeding (life-threatening)
• •Hepatic encephalopathy
• •Ascites and spontaneous bacterial peritonitis (SBP)
• •Hepatorenal syndrome
• •Hepatopulmonary syndrome / portopulmonary hypertension

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Using selective beta-blockers (metoprolol) — must use non-selective (propranolol, nadolol) to reduce both cardiac output AND splanchnic vasodilation.
• •Trap 2: Giving NSAIDs for pain — contraindicated; they worsen bleeding risk and renal function.
• •Trap 3: Over-transfusion — target Hb 7-8 g/dL (not 10-12); over-transfusion increases portal pressure and rebleeding risk.
• •Trap 4: Forgetting antibiotic prophylaxis (Ceftriaxone) in acute variceal bleed — prevents SBP and reduces mortality.
• •Trap 5: Confusing hepatorenal syndrome with pre-renal azotemia — HRS does NOT improve with fluid challenge; pre-renal does.
• •High-yield: Endoscopy is the gold standard for diagnosing varices, NOT USG.
• •High-yield: Caput medusae = dilated periumbilical veins; recanalized paraumbilical vein.
• •High-yield: In children, portal vein thrombosis is the most common cause of pre-hepatic portal HTN.

1. Definition & Pathophysiology

Hemolytic Uremic Syndrome (HUS) is a thrombotic microangiopathy characterized by the classic triad: hemolytic anemia, thrombocytopenia, and acute kidney injury (AKI). It is the most common cause of AKI in children.

• •Typical HUS (90%): Caused by Shiga toxin-producing E. coli (STEC) - O157:H7, O104:H4. Toxin binds to globotriaosylceramide (Gb3) receptors on glomerular endothelial cells → endothelial damage → platelet activation → microthrombi formation → microangiopathic hemolytic anemia + thrombocytopenia + AKI.
• •Atypical HUS (10%): Due to complement dysregulation (mutations in CFH, CFI, MCP, C3, CFHR, THBD) or secondary causes (pneumococcal infection, drugs, malignancy, autoimmune).

2. Clinical Features

• •Prodrome: Bloody diarrhea (hemorrhagic colitis) 5-10 days before HUS onset. Severe abdominal pain, vomiting.
• •Hematologic: Pallor, fatigue, petechiae, ecchymoses, mucosal bleeding (epistaxis, gingival).
• •Renal: Oliguria/anuria, edema, hypertension, hematuria, proteinuria.
• •Other: Fever, irritability, seizures (hypertensive encephalopathy), pancreatitis, cardiomyopathy, CNS involvement.

3. Investigations

4. Management

• •Supportive Care (Mainstay): Strict fluid and electrolyte management. Treat hyperkalemia, acidosis, hypertension. Blood transfusion for symptomatic anemia (Hb <6 g/dL or hemodynamic compromise). Platelet transfusion only for active bleeding or invasive procedures.
• •Nutrition: Early enteral nutrition. Parenteral nutrition if contraindicated.
• •Dialysis: Indicated for refractory fluid overload, severe hyperkalemia, severe metabolic acidosis, uremic symptoms, oliguria >24h. Peritoneal dialysis preferred in children.
• •Antibiotics: Generally AVOIDED in typical STEC-HUS (may increase Shiga toxin release). Use only for documented sepsis or pneumococcal HUS.
• •Eculizumab: Humanized anti-C5 monoclonal antibody. Indicated for atypical HUS. Extremely expensive. Vaccinate against meningococcus before starting.
• •Plasma Exchange: For severe aHUS or TTP-like presentation.
• •Other: No role for heparin, aspirin, or antiplatelet agents in typical HUS.

5. HUS Management Algorithm

6. Prognosis

• •Typical HUS: Mortality 3-5%. Most children recover fully. 30% may have long-term sequelae (proteinuria, hypertension, CKD).
• •Atypical HUS: Poor prognosis without treatment. 50% mortality/ESRD in first year. Eculizumab has dramatically improved outcomes.
• •Poor prognostic factors: Atypical HUS, CNS involvement, prolonged anuria (>7 days), severe thrombocytopenia.

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Giving antibiotics in typical STEC-HUS — AVOID; antibiotics increase Shiga toxin release and worsen outcomes.
• •Trap 2: Giving platelet transfusion routinely — contraindicated unless active bleeding or invasive procedure; can worsen thrombosis.
• •Trap 3: Confusing with TTP — TTP has severe neurological symptoms and low ADAMTS13; HUS has bloody diarrhea + normal ADAMTS13.
• •Trap 4: Forgetting vaccinate against meningococcus before eculizumab — C5 inhibition increases meningococcal risk.
• •Trap 5: Using heparin/antiplatelets in typical HUS — no role; may worsen bleeding.
• •Trap 6: Missing pneumococcal HUS — occurs after pneumonia/meningitis; different management (antibiotics indicated, not contraindicated).
• •High-yield: Negative Coombs test = non-immune hemolysis = HUS/TTP, not autoimmune hemolytic anemia.
• •High-yield: Schistocytes on peripheral smear = microangiopathic hemolytic anemia = pathognomonic.

1. Definition & Classification

Biliary Atresia (BA) is a progressive, idiopathic, obliterative cholangiopathy involving the extrahepatic (and sometimes intrahepatic) bile ducts. It is the most common cause of neonatal cholestasis and the leading indication for liver transplantation in children.

• •Type I (10%): Obliteration of common bile duct only. Most favorable prognosis.
• •Type II (2%): Obliteration of common hepatic duct.
• •Type III (88%): Obliteration of entire extrahepatic biliary tree up to porta hepatis. Most common and most severe.
• •Associated anomalies (10-20%): Biliary atresia splenic malformation (BASM) syndrome - polysplenia, situs inversus, malrotation, cardiac defects, preduodenal portal vein.

2. Clinical Features

• •Jaundice: Progressive, conjugated hyperbilirubinemia. Persists beyond 14 days of life (physiological jaundice resolves by 2 weeks).
• •Acholic (pale/white) stools: Due to absence of bile reaching intestine. Most specific sign.
• •Dark urine: Conjugated bilirubin excreted in urine.
• •Hepatomegaly: Firm, enlarged liver. Splenomegaly in advanced disease.
• •Ascites, failure to thrive, bleeding tendency, pruritus - signs of end-stage liver disease.

3. Investigations

4. Management

• •Kasai Portoenterostomy (First Line): Excision of fibrotic biliary remnant + Roux-en-Y jejunal loop anastomosed to porta hepatis to restore bile drainage. Timing is critical: Best outcomes if performed <60 days of age. Success rate drops dramatically after 90 days.
• •Pre-operative: Vitamin K (correct coagulopathy), nutritional support (MCT-containing formula), antibiotics.
• •Post-operative: Prednisolone (improve bile flow), prophylactic antibiotics (prevent cholangitis), ursodeoxycholic acid, fat-soluble vitamins (A, D, E, K).
• •Liver Transplantation: Definitive treatment for failed Kasai or end-stage liver disease. 80-90% survival at 5 years.
• •Cholangitis: Most common complication post-Kasai. Fever, increased jaundice, acholic stools. Treat with broad-spectrum IV antibiotics.

5. Prognosis

• •Kasai success (jaundice-free) in 50-60% if performed <60 days.
• •Native liver survival: 50% at 5 years, 30% at 10 years.
• •Overall survival with transplant: 80-90% at 5 years, 80% at 20 years.
• •Poor prognostic factors: Age >90 days at Kasai, Type III, BASM syndrome, post-operative cholangitis, portal hypertension.

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Calling it "physiological jaundice" beyond 14 days — ANY jaundice >14 days in a breastfed infant or >21 days in a formula-fed infant is pathological and needs workup.
• •Trap 2: Missing conjugated vs unconjugated hyperbilirubinemia — dark urine and pale stools = conjugated = obstructive = biliary atresia or neonatal hepatitis.
• •Trap 3: Delaying Kasai beyond 60 days — success rate drops dramatically; timing is the single most important prognostic factor.
• •Trap 4: Forgetting BASM syndrome associations — polysplenia, situs inversus, malrotation, cardiac defects, preduodenal portal vein.
• •Trap 5: Confusing with neonatal hepatitis — both have conjugated hyperbilirubinemia; HIDA scan and liver biopsy help differentiate.
• •Trap 6: Not giving vitamin K pre-operatively — coagulopathy from vitamin K deficiency must be corrected before surgery.
• •High-yield: Acholic stools = most specific sign; stool color card screening programs use this.
• •High-yield: Triangular cord sign (>4 mm fibrous cone at porta hepatis) on USG = highly specific for BA.

1. Definition & Pathophysiology

Diabetic Ketoacidosis (DKA) is a life-threatening complication of Type 1 DM characterized by hyperglycemia (BG >200 mg/dL), metabolic acidosis (pH <7.30), and ketonemia/ketonuria.

• •Insulin deficiency → decreased glucose utilization → hyperglycemia → osmotic diuresis → dehydration + electrolyte losses.
• •Lipolysis → increased free fatty acids → hepatic ketogenesis (beta-hydroxybutyrate, acetoacetate) → metabolic acidosis.
• •Counter-regulatory hormones (glucagon, cortisol, catecholamines, growth hormone) further worsen hyperglycemia and ketosis.

2. Clinical Features

• •Hyperglycemia symptoms: Polyuria, polydipsia, weight loss, dehydration (dry mucous membranes, poor skin turgor, tachycardia, hypotension)
• •Acidosis symptoms: Kussmaul breathing (deep, rapid, sighing respirations), acetone breath (fruity odor)
• •GI symptoms: Nausea, vomiting, abdominal pain (may mimic acute abdomen)
• •CNS symptoms: Altered consciousness, lethargy, confusion, coma (cerebral edema - most feared complication)

3. Management

• •Fluid Resuscitation: 0.9% NS 10-20 mL/kg over 1-2 hours (initial). Then 0.45-0.9% NS + dextrose. Replace deficit over 48 hours. Avoid overly rapid correction.
• •Insulin: Regular insulin 0.05-0.1 U/kg/hr IV infusion. Start AFTER 1-2 hours of fluid resuscitation. Do NOT bolus. Continue until acidosis resolves (pH >7.30, bicarbonate >18).
• •Potassium: Add 20-40 mEq/L once urine output confirmed and K+ <5.5 mEq/L. Hold insulin if K+ <3.3 mEq/L (risk of arrhythmia).
• •Bicarbonate: Generally AVOIDED. May consider if pH <6.9 with hemodynamic instability.
• •Phosphate: Replace if <1 mg/dL or cardiac dysfunction/hemolysis present.
• •Dextrose: Add D5 or D10 when BG drops to 200-250 mg/dL. Continue insulin to clear ketosis.

4. Monitoring & Complications

• •Monitoring: Blood glucose hourly, electrolytes and VBG every 2-4 hours, neuro checks hourly, fluid balance hourly, ECG monitoring.
• •Cerebral Edema (most feared): Headache, bradycardia, hypertension, altered consciousness, seizures, pupillary changes. Treat with mannitol 0.5-1 g/kg or 3% hypertonic saline 5-10 mL/kg. Reduce fluid rate, elevate head.
• •Hypoglycemia: Add dextrose to IV fluids.
• •Hypokalemia: Aggressive K+ replacement.
• •Resolution criteria: BG <200 mg/dL, pH >7.30, HCO3 >18 mEq/L, closed anion gap, ability to tolerate oral intake.

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Giving insulin bolus — NEVER bolus insulin in DKA; use continuous infusion 0.05-0.1 U/kg/hr ONLY. Bolus causes rapid osmotic shifts and cerebral edema.
• •Trap 2: Starting insulin before fluids — insulin drives K+ intracellularly; if dehydrated, this worsens hypovolemia and can cause shock. Give fluids FIRST for 1-2 hours.
• •Trap 3: Giving bicarbonate routinely — AVOID unless pH <6.9 with hemodynamic instability; bicarbonate can worsen cerebral edema and cause paradoxical CNS acidosis.
• •Trap 4: Stopping insulin when glucose normalizes — continue insulin until acidosis resolves (pH >7.30, HCO3 >18), adding dextrose to prevent hypoglycemia.
• •Trap 5: Forgetting potassium — DKA patients are TOTAL BODY K+ depleted despite normal/high serum K+. Add K+ once urine output is confirmed and K+ <5.5.
• •Trap 6: Overly rapid fluid resuscitation — increases risk of cerebral edema; replace deficit over 48 hours, not 24.
• •High-yield: Kussmaul breathing = deep, rapid, sighing respirations = respiratory compensation for metabolic acidosis.
• •High-yield: Cerebral edema = most feared complication; treat with mannitol or 3% saline.
• •High-yield: Serum K+ may be normal or high initially despite total body depletion — acidosis shifts K+ extracellularly.

📝 Exam Writing Strategy

10-mark essay: Definition (2-3 lines) → Dehydration assessment table → Plan A/B/C (pick based on vignette) → ORS composition → Zinc → Complications = ~600 words, 25 min.
3-mark short note: Definition + Dehydration signs + Management (Plan B or C) = ~150 words, 7 min.
1-mark list: ORS composition OR 4 signs of severe dehydration = bullet points only.

1. Definition & Classification

Acute diarrhea is defined as the passage of ≥3 loose or watery stools per day for <14 days. It is the second leading cause of under-5 mortality globally.

• •By duration: Acute (<14 days), Persistent (14-30 days), Chronic (>30 days)
• •By etiology: Infectious (viral, bacterial, protozoal) vs Non-infectious (lactose intolerance, IBD, celiac, antibiotic-associated)
• •By stool type: Watery diarrhea (rotavirus, cholera, ETEC) vs Dysentery/bloody diarrhea (Shigella, Salmonella, Campylobacter, EIEC)
• •Viral (70%): Rotavirus (most common, 6-24 months), Norovirus, Adenovirus, Astrovirus
• •Bacterial (20%): ETEC (traveler's diarrhea), Shigella (dysentery), Salmonella, Campylobacter, Vibrio cholerae, C. difficile
• •Protozoal (10%): Giardia lamblia, Entamoeba histolytica, Cryptosporidium

2. Assessment of Dehydration (WHO/IMNCI)

Accurate dehydration assessment drives management. Examiners test this every year.

3. Management

• •Plan A (No dehydration): Continue feeding. Give extra fluids at home. ORS 50-100 mL after each loose stool (<2 years: 50-100 mL; 2-10 years: 100-200 mL; >10 years: as much as wanted). Continue breastfeeding.
• •Plan B (Some dehydration): ORS 75 mL/kg over 4 hours in the clinic. Reassess every 1-2 hours. If vomiting, give 5 mL every 1-2 minutes by spoon/cup. Switch to Plan C if deterioration.
• •Plan C (Severe dehydration): IV fluids — Ringer Lactate (preferred) or 0.9% NS. 30 mL/kg over 30 minutes (infants <12 months) or 1 hour (children 1-5 years). Repeat if still severe. Then 70 mL/kg over next 5 hours. Reassess every 15-30 min.
• •Zinc supplementation: 10-20 mg/day for 10-14 days. <6 months: 10 mg/day; ≥6 months: 20 mg/day. Reduces duration and severity.
• •Continued feeding: NEVER stop feeds. Continue breastfeeding. Age-appropriate diet — rice, dal, khichdi, banana, yogurt. Avoid high-fiber/high-fat foods temporarily.
• •Antibiotics: NOT routine. Indicated only for: dysentery (bloody stools), cholera (rice-water stools), suspected sepsis, severe malnutrition. Shigella: Azithromycin or Ciprofloxacin. Cholera: Azithromycin single dose.
• •Antimotility agents (Loperamide): CONTRAINDICATED in children <2 years and in dysentery/bloody diarrhea.
• •Probiotics: May reduce duration by ~1 day (Lactobacillus GG, Saccharomyces boulardii). Optional adjunct.

4. ORS Composition (Low Osmolarity WHO ORS)

Examiners test this EVERY year. Memorize the composition precisely.

5. Complications

• •Dehydration: Most common. Hypovolemic shock if severe.
• •Electrolyte imbalance: Hyponatremia (most common), hypernatremia, hypokalemia, metabolic acidosis.
• •Hypoglycemia: Especially in malnourished children.
• •Acute kidney injury: Pre-renal from hypovolemia.
• •Hemolytic uremic syndrome: Post-Shiga toxin-producing E. coli (STEC) or Shigella dysenteriae type 1.
• •Prolonged/persistent diarrhea: >14 days, often due to lactose intolerance, giardiasis, or post-infectious enteropathy.
• •Secondary malnutrition: Reduced intake + malabsorption.

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Wrong ORS sodium content — 75 mEq/L in low-osmolarity ORS (NOT 90 mEq/L of old ORS).
• •Trap 2: Forgetting zinc — 10-20 mg/day for 10-14 days is standard of care and reduces duration.
• •Trap 3: Giving antibiotics for viral diarrhea — no benefit, increases resistance and complications.
• •Trap 4: Using antimotility agents in children — contraindicated, especially in dysentery.
• •Trap 5: Stopping feeds — NEVER stop breastfeeding; continue age-appropriate diet.
• •Trap 6: Wrong fluid for Plan C — Ringer Lactate preferred over NS (LR has lactate which buffers acidosis).
• •Trap 7: Hypernatremic dehydration management — treat with 0.45% NS or ORS, NOT rapid free water; correct slowly over 48h to avoid cerebral edema.
• •High-yield: Skin pinch is the most reliable sign of dehydration across all age groups.
• •High-yield: Cholera stools = rice-water stools — massive watery diarrhea with flecks of mucus; treat with ORS + Azithromycin.
• •High-yield: ORS mechanism = glucose-sodium cotransport (SGLT1) in the small intestine; 1:1 molar ratio optimizes absorption.

📝 Exam Writing Strategy

10-mark essay: Definition + Risk factors + Age-wise clinical features + Investigations (culture gold standard) + Management (cystitis vs pyelonephritis) + VUR grading = ~600 words, 25 min.
3-mark short note (PYQ 2022): Definition + E. coli (80%) + Clinical features + Oral antibiotics (Cotrimoxazole/Cephalexin 3-5 days) + Fluids = ~150 words, 7 min.
1-mark list: VUR grades I-V OR Urine culture criteria.

1. Definition & Risk Factors

Urinary Tract Infection (UTI) is defined by significant bacteriuria (≥10⁵ CFU/mL of a single pathogen on clean-catch urine, or any growth on suprapubic aspirate) with pyuria (>5 WBCs/hpf).

• •Age & sex distribution: More common in males <1 year (uncircumcised); females predominate after 1 year. Peak incidence at 2-5 years.
• •Predisposing factors: Vesicoureteral reflux (VUR) — most important; posterior urethral valves (PUV) in males; neurogenic bladder; constipation; labial adhesions; renal stones; catheterization.
• •Common pathogens: E. coli (80-90%) — P-fimbriated strains adhere to uroepithelium. Others: Klebsiella, Proteus (struvite stones), Enterococcus, Pseudomonas.
• •Route of infection: Ascending (most common), hematogenous (less common, causes renal abscess).

2. Clinical Features

Symptoms vary dramatically by age. Examiners love testing the nonspecific presentation in infants.

3. Investigations

4. Management

• •Outpatient (uncomplicated cystitis, >2 months, well-appearing): Oral antibiotics for 3-5 days. First-line: Cotrimoxazole (TMP-SMX) or Nitrofurantoin or Cephalexin. Avoid nitrofurantoin if GFR <30.
• •Inpatient (pyelonephritis, <2 months, septic, vomiting, unable to tolerate oral): IV antibiotics for 7-14 days. First-line: Cefotaxime or Ampicillin + Gentamicin. Ceftriaxone avoided in infants <2 months. Switch to oral when afebrile for 24-48h.
• •Neonates (<1 month): ALWAYS admit. IV Ampicillin + Gentamicin (or Ampicillin + Cefotaxime) for 10-14 days. Ceftriaxone is contraindicated in neonates due to bilirubin displacement and kernicterus risk.
• •Duration: Cystitis — 3-5 days; Pyelonephritis — 10-14 days; Recurrent UTI prophylaxis — nightly low-dose antibiotic (Nitrofurantoin or Cotrimoxazole) for 3-6 months.
• •Supportive: Paracetamol for fever, adequate hydration, urine alkalinization for pain (not routine).
• •VUR management: Grades I-II — conservative (prophylactic antibiotics, treat constipation, timed voiding, double voiding). Grades III-V — surgical intervention (endoscopic Deflux injection or ureteric reimplantation).
• •Circumcision: Reduces UTI risk in males by 90% — consider if recurrent UTIs in uncircumcised boys.

5. Recurrent UTI & Vesicoureteral Reflux (VUR)

Recurrent UTI = ≥2 UTIs in 6 months or ≥3 in 1 year. Always investigate for underlying abnormalities.

• •VUR grading (International Reflux Study):
• • Grade I: Into ureter only
• • Grade II: Into ureter, pelvis, and calyces without dilation
• • Grade III: Mild-moderate dilation of pelvis and calyces, minimal blunting of calyces
• • Grade IV: Moderate dilation and tortuosity of ureter, blunting of calyces
• • Grade V: Gross dilation, tortuous ureter, loss of papillary impressions
• •Screening siblings: 30% of siblings of children with VUR also have VUR.
• •Natural history: Grades I-II resolve spontaneously in 80% by 5 years. Grades III-V rarely resolve; require intervention.
• •Renal scarring: Leading cause of hypertension and CKD in children. Prevent by prompt UTI treatment and VUR management.

🎯 Examiner Traps & High-Yield Points

• •Trap 1: Treating UTI based on dipstick alone — ALWAYS send urine culture before starting antibiotics in first UTI.
• •Trap 2: Missing nonspecific presentation in infants — fever without source in <2 years = UTI until proven otherwise.
• •Trap 3: Wrong duration — cystitis = 3-5 days; pyelonephritis = 10-14 days. Too short = recurrence; too long = resistance.
• •Trap 4: Forgetting prophylaxis for recurrent UTI — nightly low-dose antibiotic (Nitrofurantoin or Cotrimoxazole) for 3-6 months.
• •Trap 5: Not investigating VUR after first febrile UTI in <2 years — USG KUB + MCU indicated.
• •Trap 6: Using nitrofurantoin for pyelonephritis — poor tissue penetration; reserve for cystitis only.
• •Trap 7: Not screening siblings of VUR patients — 30% prevalence in siblings.
• •High-yield: E. coli P-fimbriae = most important virulence factor; adheres to uroepithelium.
• •High-yield: VUR + UTI = renal scarring = hypertension + CKD. Prevention is key.
• •High-yield: Suprapubic aspiration = gold standard for urine collection in infants; ANY growth = UTI.

1. Definition & Pathophysiology

Vesicoureteral Reflux (VUR) is the retrograde flow of urine from the bladder into the ureter and sometimes the renal pelvis/calyces. It is the most common urologic anomaly in children, affecting 1-2% of the pediatric population and up to 30-40% of children with UTI.

• •Primary VUR (most common): Due to inadequate length of the intravesical ureter (submucosal tunnel). The ureterovesical junction (UVJ) valve mechanism is incompetent. Associated with lateral ectopia of ureteric orifice (laterally placed orifices have shorter submucosal tunnels).
• •Secondary VUR: Due to increased intravesical pressure overcoming a normal UVJ. Causes: posterior urethral valves (PUV), neurogenic bladder, bladder outlet obstruction, severe constipation, prune belly syndrome.
• •Embryology: The ureteric bud arises from the mesonephric duct. Abnormal cranial migration of the bud leads to lateral ectopia of the orifice and shortened intravesical ureter → primary VUR.

2. Grading (International Reflux Study Committee)

Memorize this grading — examiners test it directly.